ISRCTN53643604已完成2 期
Randomised phase II trial comparing intensive induction chemotherapy (CBOP BEP) with standard BEP chemotherapy in poor prognosis male germ cell tumours
Medical Research Council (MRC) (UK)0 个研究点目标入组 89 人开始时间: 2004年10月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 89
研究概览
简要总结
2015 Results article in http://www.ncbi.nlm.nih.gov/pubmed/25001888 results 2020 Results article in https://www.ncbi.nlm.nih.gov/pubmed/32007714 results (added 03/02/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Non-seminomatous germ cell tumour of any extracranial primary site
- •2. Poor prognosis features, as defined by the International Germ Cell Cancer Collaborative Group (IGCCCG) criteria
- •3. Performance status 0 - 3
- •4. Globular filtration rate greater than 50 ml/min
- •5. No comorbid condition
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
2 期
A two-arm phase II randomised trial of intermittent chemotherapy plus continuous cetuximab and of intermittent chemotherapy plus intermittent cetuximab in first line treatment of patients with K-ras-normal (wild-type) metastatic colorectal cancerColorectal cancerMetastatic colorectal cancerCancerISRCTN38375681Medical Research Council (MRC) (UK)130
已完成
2 期
A phase II, double-blind, randomised, controlled, dose ranging study to evaluate the safety, immunogenicity, dose response and schedule response of a meningococcal A conjugate vaccine administered concomitantly with local expanded program on immunisation (EPI) vaccines in healthy infantsBacterial meningitisNervous System DiseasesISRCTN82484612Serum Institute of India Limited1,200
已完成
2 期
stekinumab in adolescents with recent-onset type 1 diabetesNutritional, Metabolic, EndocrineType 1 diabetes mellitusISRCTN14274380Cardiff University88
已完成
2 期
Scheduling nabpaclItaxel with gemcitabine (SIEGE)Topic: CancerSubtopic: Upper Gastro-Intestinal CancerDisease: PancreasMalignant neoplasm of pancreas - Pancreatic ductCancerISRCTN71070888Cambridge University Hospitals NHS Foundation Trust (UK)146
已完成
2 期
Cediranib maleate with or without gefitinib in treating patients with recurrent or progressive glioblastomaCancerISRCTN00549973niversity College London (UK)38